These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32998994)

  • 1. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
    Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
    Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
    Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
    Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.
    Nair J; Huang TT; Murai J; Haynes B; Steeg PS; Pommier Y; Lee JM
    Oncogene; 2020 Aug; 39(33):5520-5535. PubMed ID: 32647134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
    Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
    Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
    [No Abstract]   [Full Text] [Related]  

  • 5. Protein kinase C iota promotes glycolysis via PI3K/AKT/mTOR signalling in high grade serous ovarian cancer.
    Tyagi K; Roy A; Mandal S
    Mol Biol Rep; 2024 Sep; 51(1):983. PubMed ID: 39276277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
    Do KT; Kochupurakkal B; Kelland S; de Jonge A; Hedglin J; Powers A; Quinn N; Gannon C; Vuong L; Parmar K; Lazaro JB; D'Andrea AD; Shapiro GI
    Clin Cancer Res; 2021 Sep; 27(17):4710-4716. PubMed ID: 34131002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
    Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
    Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    Cho HY; Kim YB; Park WH; No JH
    Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer.
    Evangelisti G; Barra F; Moioli M; Sala P; Stigliani S; Gustavino C; Costantini S; Ferrero S
    Expert Opin Investig Drugs; 2020 Aug; 29(8):779-792. PubMed ID: 32539469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
    Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.
    Sanij E; Hannan KM; Xuan J; Yan S; Ahern JE; Trigos AS; Brajanovski N; Son J; Chan KT; Kondrashova O; Lieschke E; Wakefield MJ; Frank D; Ellis S; Cullinane C; Kang J; Poortinga G; Nag P; Deans AJ; Khanna KK; Mileshkin L; McArthur GA; Soong J; Berns EMJJ; Hannan RD; Scott CL; Sheppard KE; Pearson RB
    Nat Commun; 2020 May; 11(1):2641. PubMed ID: 32457376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
    Giudice E; Huang TT; Nair JR; Zurcher G; McCoy A; Nousome D; Radke MR; Swisher EM; Lipkowitz S; Ibanez K; Donohue D; Malys T; Lee MJ; Redd B; Levy E; Rastogi S; Sato N; Trepel JB; Lee JM
    Nat Commun; 2024 Mar; 15(1):2805. PubMed ID: 38555285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
    Warren NJH; Eastman A
    J Biol Chem; 2019 Feb; 294(6):1763-1778. PubMed ID: 30573684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FANCD2 expression affects platinum response and further characteristics of high grade serous ovarian cancer in cells with different genetic backgrounds.
    Taylor SJ; Hollis RL; Gourley C; Herrington CS; Langdon SP; Arends MJ
    Exp Mol Pathol; 2024 Aug; 138():104916. PubMed ID: 38959632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse.
    Urrutia G; Salmonson A; Toro-Zapata J; de Assuncao TM; Mathison A; Dusetti N; Iovanna J; Urrutia R; Lomberk G
    Mol Cancer Res; 2020 Mar; 18(3):448-462. PubMed ID: 31822519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.